Stocks · News reference

Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582

Aug 6, 2026, 6:23 PMBenzinga Newsdesk

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $575 to $582.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 21, 2026, 5:52 PMBenzinga Newsdesk
Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
Read original at benzinga
PRAX
BenzingaAug 7, 2026, 8:03 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
Read original at benzinga
PRAX
BenzingaAug 7, 2026, 1:57 PMBenzinga Newsdesk
Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362
Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
Read original at benzinga
PRAX